Harvard Bioscience, Inc. Acquires CMA Microdialysis’ Preclinical Business
HOLLISTON, Mass. – Harvard Bioscience, Inc. (Nasdaq:HBIO – News), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, today announced that it has acquired the preclinical business unit of CMA Microdialysis AB through a purchase of assets.
CMA Microdialysis AB is a privately held Swedish manufacturer of microdialysis products. Founded in 1984, the company pioneered the microdialysis technique for in vivo sampling and monitoring of organs and tissues. This acquisition is complementary to the current Harvard Apparatus research products for neuroscience applications.
Chane Graziano, CEO of Harvard Bioscience, commented, “The acquisition of CMA Microdialysis’ preclinical business provides Harvard with a leading technology to add to our line of specialized tools for biological research. The business unit will remain in Sweden under the leadership of Erik During. We expect this acquisition to be immediately accretive to earnings.”
Philip Siberg, CEO of CMA Microdialysis, added, “We are pleased to announce this transaction because of the growth opportunity and long-term strategic value it creates for our employees and our customers. As part of the transaction, Harvard Bioscience, Inc. will acquire the rights to the name CMA Microdialysis. CMA Microdialysis will be renamed to Dipylon Medical AB (www.dipylonmedical.com) with continued focus on the development and marketing of clinical microdialysis solutions for human use. In addition, the leading Eirus system for continuous glucose monitoring for intensive care will continue to be developed within the new entity Eirus Medical.”
About Harvard Bioscience
Harvard Bioscience (“HBIO”) is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments, used to advance life science research and regenerative medicine. HBIO sells products to thousands of researchers in over 100 countries primarily through our 850 page catalog (and various other specialty catalogs), our website, through distributors, including GE Healthcare, Thermo Fisher Scientific and VWR, and via our field sales organization. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Germany and Spain with additional facilities in France and Canada. For more information, please visit www.harvardbioscience.com.

